Literature DB >> 2154269

Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells.

G M Rodgers1, M T Conn.   

Abstract

Elevated blood levels of homocysteine are associated with atherosclerosis and thrombotic disease. We previously reported that treatment of cultured endothelial cells with homocysteine increased endogenous factor V activity by activation of the cofactor. Because endothelial cell-associated factor Va would be regulated by the protein C mechanism, the ability of homocysteine-treated arterial and venous endothelial cells to activate protein C was investigated. Both arterial and venous endothelial cells activated protein C; 0.6 mmol/L homocysteine reduced endothelial cell protein C activation by 12%. Maximal inhibition (90%) of protein C activation occurred with 7.5 to 10 mmol/L homocysteine after 6 to 9 hours of incubation. Metabolism of homocysteine was not accelerated by cultured endothelial cells. Investigation of the mechanism(s) by which homocysteine reduced protein C activation indicated that the metabolite did not induce an inhibitor to activated protein C, but in low concentrations acted as a competitive inhibitor to thrombin. These data suggest that perturbation of the vascular endothelial cell protein C mechanism by homocysteine may contribute to the thrombotic tendency seen in patients with elevated blood levels of this metabolite.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154269

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Blood levels of homocysteine and atherosclerotic vascular disease.

Authors:  W G Christen; P M Ridker
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis.

Authors:  P A Isotalo; J G Donnelly
Journal:  Mol Diagn       Date:  2000-03

3.  Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.

Authors:  S R Lentz; C G Sobey; D J Piegors; M Y Bhopatkar; F M Faraci; M R Malinow; D D Heistad
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 4.  Hyperhomocysteinaemia and associated disease.

Authors:  R C Bakker; D P Brandjes
Journal:  Pharm World Sci       Date:  1997-06

5.  Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition.

Authors:  Hong Wang; XiaoHua Jiang; Fan Yang; Gary B Chapman; William Durante; Nicholas E S Sibinga; Andrew I Schafer
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 6.  Atherosclerotic vascular disease: will folate or gene therapy be useful?

Authors:  D D Heistad; S R Lentz; C D Rios
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

Review 7.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

8.  Genetic variants associated with protein C levels.

Authors:  C Y Vossen; B P Koeleman; S J Hasstedt; I J Nijman; I J Renkens; P W Callas; F R Rosendaal; E G Bovill
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

Review 9.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

10.  Atherosclerosis, cholesterol, nutrition, and statins--a critical review.

Authors:  Jan-Olaf Gebbers
Journal:  Ger Med Sci       Date:  2007-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.